Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5

References

• Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral estrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282–5
   PubMedGoogle Scholar
• Aro JL, Happiainen RK, Rannikko SA, Alfthan OS. High dose polyestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 1989; 63: 512–4
   PubMedGoogle Scholar
• Lukkarinen O, Kontturi M, Finnish Zoladex Multicentre Study Group. Comparison of long-acting LHRH agonist and polyestradiol phosphate in the treatment of advanced prostatic carcinoma. Scand J Urol Nephrol 1994;28:171–8.
   PubMed Web of Science ®Google Scholar
• Stege R, Carlström K, Collste L, Eriksson A, Henriksson P, Pousette A. Single-drug parenteral estrogen treatment in prostatic cancer: a study of two maintenance-dose regimens. Prostate 1989; 14: 183–8
   PubMed Web of Science ®Google Scholar
• Henriksson P, Carlström K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, et al. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics and endocrine and clinical effects of a parenteral estrogen regimen. Prostate 1999; 40: 76–82
   PubMed Web of Science ®Google Scholar
• Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, et al. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988; 13: 257–61
   PubMed Web of Science ®Google Scholar
• Hedlund PO, Henriksson P, Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study Group. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology 2000;55:328–33.
   PubMed Web of Science ®Google Scholar
• Esposti P. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. Scand J Urol Nephrol 1971; 5: 199–209
   PubMedGoogle Scholar
• Mostofi FK, Sesterhenn IA, Sobin LH. Histologic typing of prostate tumors. World Health Organization, Geneva 1980; 17–21
   Google Scholar
• Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017–21
   PubMed Web of Science ®Google Scholar
• Andersson L. Design of clinical trials on prostate cancer. Urology 1997; 49(Suppl 4A)39–45
   PubMed Web of Science ®Google Scholar
• Hedlund PO, Ala-Opas Martti, Brekkan E, Damber JE, Damber L, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scand J Urol Nephrol 2002; 36: 405–13
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Frödin T, Ålund G, Varenhorst E. Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer. Prostate 1985; 7: 203–8
   PubMed Web of Science ®Google Scholar
• Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657–80
   PubMedGoogle Scholar
• Hedlund PO, Gustafson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt®) or conventional estrogen. Scand J Urol Nephrol Suppl 1980; 55: 103–5
   PubMedGoogle Scholar
• Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate. Scand J Urol Nephrol 2005; 39: 294–300
   PubMed Web of Science ®Google Scholar
• Henriksson P, Blombäck M, Bratt G, Edhag O, Eriksson A, Vesterqvist O. Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancer. Med Oncol Tumor Pharmacother 1989; 3: 219–25
   Google Scholar
• Blombäck M, Hedlund PO, Säwe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer – predictors for cardiovascular complications?. Thromb Res 1988; 49: 111–21
   PubMed Web of Science ®Google Scholar
• Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282–5
   PubMedGoogle Scholar
• Eisen M, Napp HE, Vock R. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate. J Urol 1975; 114: 93–7
   PubMed Web of Science ®Google Scholar
• Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979–83
   PubMed Web of Science ®Google Scholar
• Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006 Sep 20; 24: 4448–56
   PubMed Web of Science ®Google Scholar
• Sternberg CN. Apples and oranges. RE: 7.4 year update of the ongoing bicalutamide early prostate cancer (EPC) trial program. Br J Urol Int 2006; 97: 435–8
   Google Scholar
• Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 2007; 41: 456–77
   PubMed Web of Science ®Google Scholar
• Aus G, Abbou CC, Bolla M, Heidenreich L, Schmid HP, Van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005; 48: 546–51
   PubMed Web of Science ®Google Scholar
• Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311: 1281
   PubMed Web of Science ®Google Scholar
• Cox RL, Crawford D. Estrogens in the treatment of prostate cancer. J Urol 1995; 154: 1991–8
   PubMed Web of Science ®Google Scholar
• Spetz AC, Hammar M, Lindberg B, Spångberg S, Varenhorst E. Prospective evaluation of hot flushes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001; 166: 518
   Web of Science ®Google Scholar